Jacqueline Hess Joins Immunophotonics Board of Directors

Immunophotonics, a clinical-stage biotech firm, has announced the addition of Jacqueline Hess to its Board of Directors. With over three decades of experience in steering and advising heavily regulated trans-Atlantic businesses, Hess is expected to significantly contribute to the strategic direction and growth of the company. Currently Vice Chair of the Board of Vontobel Swiss Financial Advisers and a former CEO of the same, Hess also holds board positions with Companion Spine LLC and The Boardroom in Switzerland. Immunophotonics, based in St. Louis, USA, and Bern, Switzerland, is focusing on immuno-oncology. Its lead asset, IP-001, is being tested in multiple clinical trials to induce systemic cancer immune responses. The leadership sees Hess's biotech industry expertise and global perspective as pivotal to reaching their goal of improving cancer patient outcomes.